Inspire Medical Systems, Inc.

INSP

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

RA Capital Management Driehaus Capital Rock Springs Capital

Position Trend

Feb 13, 2026

$40.6M

1 fund

Feb 17, 2026

$196.2M

4 funds

+383% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 141,964Value: $13.1M

# Signal Note: RA Capital Entry into INSP RA Capital's $13.1M initiation in Inspire signals confidence in the company's sleep apnea market expansion, particularly as reimbursement for remote patient monitoring improves and competitive pressures from CPAP alternatives intensify. The timing suggests conviction ahead of potential upcoming data readouts or commercial inflection points in their implantable device franchise, which addresses the large underdiagnosed OSA market (~80% untreated in the US).

Driehaus CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds RNA3 funds WVE3 funds PRAX3 funds OLMA2 funds MLYS2 funds PTN2 funds AMLX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Driehaus Initiates $32.1M Position in INSP Driehaus Capital's entry into Inspire Medical signals conviction in the company's sleep apnea device franchise, which generated $165M in 2023 revenue with 30%+ YoY growth driven by expanded reimbursement and patient awareness. The $32.1M stake (348.5k shares) suggests positioning ahead of potential 2024-2025 catalysts including international expansion (EU market) and pipeline advancement in adjacent respiratory conditions. At current market cap (~$800M), this represents a meaningful allocation for a growth-focused manager, indicating confidence in the company's path to sustained high-double-digit growth and potential profitability inflection.